Purpose To evaluate feasibility, disease control, survival, and toxicity after adaptive 18 F-fluorodeoxyglucose (FDG) positron emisson tomography (PET) guided radiotherapy in patients with recurrent and second primary head and neck squamous cell carcinoma. Methods A prospective trial investigated the feasibility of adaptive intensity modulated radiotherapy (IMRT) ± concomitant cetuximab in 10 patients. The primary endpoint was achieving a 2-year survival free of grade >3 toxicity in ≥30% of patients. Three treatment plans based on 3 PET/CT scans were consecutively delivered in 6 weeks. The range of dose painting was 66.0-85.0 Gy in the dose-painted tumoral volumes in 30 fractions. Results Two-year locoregional and distant control rates were 38 and 76%, respectively. Overall and disease-free survival at 2 years was 20%. No grade 4 or 5 acute toxicity was observed in any of the patients, except for arterial mucosal hemorrhage in 1 patient. Three months after radiotherapy, grade 4 dysphagia and mucosal wound healing problems were observed in 1/7 and 1/6 of patients, respectively. Grade 5 toxicity (fatal bleeding) was seen in 2 patients, at 3.8 and 4.1 months of follow-up. Data on 2-year toxicity could only be assessed in 1 of the 2 surviving patients, in whom grade 4 mucosal wound healing problems were observed; no other grade >3 toxicity was observed. In this respect, a 30% 2-year survival free of grade >3 toxicity will not be achieved. Conclusions Adaptive PET-guided reirradiation is feasible. However, due to slow accrual and treatment results that seemed inconsistent with achieving the primary endpoint, the trial was stopped early. Machbarkeitsstudie zur adaptiven 18 F-FDG-PET-gestützten Radiotherapie bei rezidivierenden und sekundären Kopf-Hals-Tumoren in zuvor bestrahltem Gebiet Zusammenfassung Zielsetzung Bewertung der Machbarkeit, der Seuchenbekämpfung, des Überlebens und der Toxizität nach adaptiver 18 F-FDG-PET-geleiteter Strahlentherapie in Patienten mit rezidivierten und sekundären Kopf-Hals-Tumoren. Methoden Die prospektive Studie untersuchte die Machbarkeit der adaptiven Strahlentherapie ± Cetuximab bei 10 Patienten. Der primäre Endpunkt war das Erreichen einer 2-Jahres-Überlebensrate ohne Toxizitätsgrad >3 bei ≥30% der Patienten. Drei Behandlungspläne basierend auf 3 PET/CT-Scans wurden nacheinander in 6 Wochen geliefert. Die Reichweite des "Dose painting" in den "dose-painted" Tumorvolumen betrug 66,0-85,0 Gy in 30 Fraktionen. Ergebnisse Lokoregionale und ferne 2-Jahres-Kontrollrate waren jeweils 38 und 76%. Allgemeines und krankheitsfreies Überleben nach 2 Jahren waren 20%. Keine akute Toxizität vom Grad 4 oder 5 wurde beobachtet, mit Ausnahme von arterieller Schleimhautblutung bei einem Patienten. Drei Monate nach der Strahlentherapie wurden Dysphagie und Wundheilungsprobleme vom Grad 4 bei jeweils 1/7 und 1/6 Patienten beobachtet. Eine Grad-5-Toxizität (tödliche Blutung) wurde bei 2 Patienten gesehen, jeweils 3,8 und 4,1 Monate nach der Strahlentherapie. Späte Toxizität nach 2 Jahren konnte nur bei einem von zwei überlebenden Patienten beurteilt werden, bei dem Grad-4-Wundheilungsprobleme beobachtet wurden; es wurde keine andere Toxizität vom Grad >3 festgestellt. In dieser Hinsicht wird ein 2-Jahres-Überleben ohne Toxizitätsgrad >3 bei 30% nicht erreicht. Schlussfolgerung Adaptive PET-geleitete Wiederbestrahlung ist machbar. Allerdings wurde die Studie aufgrund langsamen Zuwachsens und den mit dem primären Endpunkt unvereinbaren Behandlungsergebnissen frühzeitig beendet.
Introduction
Despite improvements in primary therapy for head and neck squamous cell carcinoma (HNSCC), 46-60% and 3-9% of patients develop recurrent and second primary cancers of the head and neck, respectively. These tumors in previously irradiated territory create challenging management strategies, with lower probability of long-term disease control and increased morbidity rates [1] [2] [3] . Over the past decades, salvage surgery has proven to be the most effective curative-intent retreatment option [1] . However, in more advanced stages or in patients with medical conditions rendering surgery impossible, inferior results are reported in the few trials available on high-dose reirradiation (RI) ± systemic therapy for recurrent or second primary head and neck cancer. Also, there is a lack of prospective RI trials, possibly due to slow accrual and high rates of severe, dose-limiting late toxicity and more treatment-related deaths, which makes medical decision-taking difficult [1] [2] [3] . The alternative, i. e., systemic palliative therapy, remains the current standard of care in many centers, although the scheme that has been proven to result in the best survival (combined cisplatin-5-fluorouracil-cetuximab) only results in a modest median survival of 10.1 months and does not offer realistic chances of cure [4] .
In an effort to reduce the dose to swallowing structures and to organs at risk (OARs) in previously irradiated regions, the replanning strategy in adaptive radiotherapy (ART) might be beneficial, as per-treatment changes in tumor and OARs and associated suboptimal dose distributions could be corrected. Secondly, implementation of 18 F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)-guided RI planning could identify more aggressive and/or radioresistant parts of the tumor, allowing doseadaptation based on biological tumor characteristics and improving local disease control [5] .
Therefore, a multicenter prospective trial was initiated to investigate whether three-phase adaptive 18 F-FDG-PETguided RI can improve locoregional control (LRC) at minimized treatment-induced toxicity in recurrent and second primary HNSCC in previously irradiated territory.
Materials and methods

Study design and patients
A prospective, non-controlled, non-randomized feasibility trial was designed and conducted in two centers and registered on www.clinicaltrials.gov with identifier NCT01427010. Patients with histologically proven recurrent or second primary squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx in previously irradiated territory could be included. Patients with grade 3 or more late toxicity, except xerostomia, and/or treatment interval <12 months after initial (chemo)radiotherapy ([C]RT) for primary head and neck cancer, previous radiotherapy (RT) for cT1-2 cN0 M0 glottic cancer, and distant metastases were excluded. Because of the repeated iodine contrast-enhanced computed tomography (CT), patients with renal insufficiency (estimated glomerular filtration rate <60 mL/min) or iodine contrast allergy were not allowed. Standard patient work-up was performed according to the institutional guidelines and decision for curative RT with or without concomitant cetuximab (bio-RT; BRT) was made during a multidisciplinary meeting with radiation oncologists, medical oncologists, and head and neck surgeons at both participating centers. No patients received cetuximab after radiation therapy. Minimum age was 18 years with a Karnofsky performance status ≥70%.
Twenty patients were planned to be included in this trial. Primary objectives were to evaluate the feasibility of adaptive 18 F-FDG-PET-guided intensity-modulated RT (IMRT) in treatment of recurrent or second primary HNSCC in the previously irradiated territory and to achieve a 2-year grade >3 toxicity-free survival in 30% of the patients. Secondary endpoints were acute toxicity, tumor response 3 months after RT, and time to progression.
No stopping rules were predefined at the moment of the composition of the trial. In this era, it would be the case.
Treatment protocol
Treatment protocol is given in Fig. 1 .
All patients received adaptive IMRT (step-and-shoot or helical tomotherapy), consisting of 3 treatment plans in 6 weeks: plan 1 (fractions 1-10), based on a pretreatment 18 F-FDG-PET/CT, and plans 2 (fractions 11-20) and 3 (fractions [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , based on a per-treatment 18 F-FDG-PET/CT or 18 F-FDG-PET and CT obtained after fraction 8 and 18, respectively. In one patient, the per-treatment 18 F-FDG-PET after fraction 8 could not be performed due to technical problems. During imaging and treatment, patients were immobilized using a neck support and a customized RT mask. If a multidisciplinary decision for concomitant systemic therapy was taken, patients received a cetuximab loading dose (400 mg/m 2 ) 1 week before start of RT, followed by weekly doses of 250 mg/m 2 up to six times concomitant with RT.
Target definition
Targets and OARs were delineated on pre-and per-treatment 18 F-FDG-PET/CT or rigidly fused 18 F-FDG-PET and CT, with gross tumor volume (GTV) delineation based on both biological and anatomical (i. e., CT and/or magnetic resonance imaging [MRI]) imaging. The metastatic lymph nodes were delineated on CT and included in the lymph node GTV (GTVLN). The same window and level of 18 F-FDG-PET and CT images were used in all patients. Clinical target volume (CTV) was obtained by three-dimensional expansion of the GTV with a 0.5 cm margin, adjusted to the air cavities and uninvolved bones or muscles. A margin of 3 mm was added to the CTV and/or GTVLN to create the planning target volume (PTV) and PTVLN. There was no elective neck irradiation.
The delineated OARs were spinal cord, brainstem, parotid glands, mandible, and swallowing structures (pharyngeal constrictor muscles, cricopharyngeal muscle/upper esophageal sphincter, esophagus, and supraglottis). To obtain planning risk volumes (PRVs), the spinal cord and brainstem were expanded with a 5 and 3 mm margin, respectively.
Treatment planning
The IMRT plans were created and optimized using an inhouse developed extension based on the GRATIS software (Sherouse Systems Inc., Chapel Hill, NC, USA) with integrated planning and optimization tools (institution 1; [6, 7] ) and the commercially available treatment planning systems of TomoTherapy (TomoTherapy Inc., Madison, WI, USA; institution 2). In institution 1, step-and-shoot IMRT was given on an Elekta Synergy linear accelerator (Elekta [39] AB, Stockholm, Sweden) with 6 MV photons in the axial plane with a 5-7 beam set-up. The beam incidences depended on the location of the target volumes and OARs, and were manually chosen by dedicated physicists and a radiation oncologist. In institution 2, helical tomotherapy plans were made on the TomoTherapy planning software version HD 1.0 for a TomoHD system [8] . A field width of 2.5 cm, a maximum modulation factor of 2.8, and a pitch of 0.287 have been used [9] .
The methodology of 18 F-FDG-PET voxel intensity-based step and shoot IMRT planning has been described previously by Duprez et al. [10] . Methodology of using 18 F-FDG-PET for dose painting in helical tomotherapy was based on an article of Deveau et al. [11] . After definition of 4 to 7 (in function of the tumor size) 18 F-FDG-PET-intensity based subvolumes with the MIM contouring software (MIM Software Inc., Cleveland, OH, USA), these subvolumes were sent over to the TomoTherapy planning software and plans were made following the guidelines described in Fig. 1 .
Three consecutive plans of 10 fractions were planned with a dose prescription for a dose range as given in Fig. 1 .
Treatment planning objectives for the targets, OARs, and their PRVs are presented in Table 1 .
Patient set-up errors were corrected daily using kV cone beam CT or MV helical CT.
Patient evaluation and statistical analysis
Acute toxicity was scored weekly during treatment according to the common toxicity criteria (CTC version 2; [12] ), including dysphagia, mucositis, pain, and dermatitis. Additionally, weight and need for hospitalization were monitored. The highest scores during treatment were registered for further analysis.
To evaluate subacute and late toxicity, the LENT/SOMA scales [13] were obtained at 3, 6, 12, 16, and 24 months after the end of RT. Subacute and late toxicity were defined as toxicity occurring or persisting at ≥3 months and ≥6 months post-RT, respectively.
During follow-up, disease control was evaluated by clinical examination, with control 18 F-FDG-PET/CT at 3 months and videofluoroscopic oropharyngeal motility study at 6 and 12 months post-treatment. In case of clinical suspicion of recurrence or other problems, additional imaging (e. g., CT Hard dose/volume constraints are in italics PTV planning target volume, OAR organ at risk, PRV planning OAR volume, GTV gross tumor volume, GTVLN gross tumor volume of the metastatic lymph nodes, Dx dose level on the DVHs above which lay x% of the contoured volume where x = 2, 50, and 95, Vx relative volume OAR receiving at least x Gy, where x = 27, 50, 60, or 70, Dp maximum of the previously delivered dose to OAR a Dose inhomogeneity calculated as (D2-D98)/Dmedian, where Dx = dose level on the DVHs above which lay x% of the contoured volume where x = 2, 50, and 98 and/or MRI) was performed. Locoregional (LRC) and distant disease control (DC), and overall (OS) and diseasefree survival (DFS) were obtained until May 2016 and analyzed using Kaplan-Meier statistics. Time to progression was calculated from the start of RT. Changes in GTV, CTV, and PTV due to the adaptive treatment planning and changes in maximum standardized uptake value (SUVmax) on PET during therapy were compared using the Wilcoxon test.
A p-value smaller than 0.05 was considered statistically significant. All statistics were performed using SPSS Statistics, version 24.0 (IBM, Armonk, NY, USA). 
Results
Patients and treatment outcome
Ten patients with recurrent (n = 5) or second primary (n = 5) HNSCC were reirradiated between January 2012 and March Table 2 . Median dose of the initial RT was 67.6 Gy. Median time interval from initial RT to RI was 4.9 years. One patient did not complete the treatment course because of arterial bleeding during BRT, treated with coagulation and eventually embolization of the right external carotid artery. At the time of analysis, only 2 patients were still alive.
Disease control and survival
Response evaluation with 18 F-FDG-PET/CT (n = 7), CT alone (n = 2), or endoscopy (n = 1) 3 months after RI showed complete response in 3 patients, partial response in 4 patients, and progressive disease in 3 patients. Eventually, disease progression was observed in 6 patients with a median time to progression of 4.7 months.
Five patients died within 6 months of follow-up due to cancer progression (n = 3) or fatal bleeding (n = 2). Within 2 years of follow-up, another 3 patients died because of cancer progression (n = 2) or unknown cause (n = 1).
At 2 years of follow-up, LRC and DC were 38% and 76%, respectively, and OS and DFS were both 20% (Fig. 2) . All locoregional recurrences were in-field, except for 1 patient, who had regional recurrence outside the PTV (lymph node region Ia, dose 10-20 Gy) and metastatic axillary and mediastinal lymph nodes. Estimated median OS and DFS were 4.5 months.
Toxicity
Results on acute, subacute, and late toxicity can be found in Table 3 . One patient experienced arterial mucosal bleeding during treatment. No other grade >3 acute toxicity, weight loss ≥10%, or hospitalization during RT was observed in any of the other patients. At 3 months of follow-up, grade 4 dysphagia and mucosal wound healing problems were observed in 1/7 and 1/6 patients, respectively. Two patients (20%) died because of fatal bleeding with origin in ulcerated mucosal tissue in the reirradiated region, at 3.8 and 4.1 months of follow-up, respectively. In the absence of evidence that these bleedings were caused by tumoral relapse, they have been scored as grade 5 toxicity. Only 2 patients were assessable for late radiation toxicity scoring, with grade 4 mucosal wound healing problems in 1 patient at 6, 12, and 16 months of follow-up; no other grade >3 toxicity was observed in these 2 patients at 6, 12, and 16 months of follow-up. Due to logistic problems, the results on late toxicity at 24 months of follow-up could only be assessed in one patient. In this patient, persistent grade 4 mucosal wound healing problems were observed 2 years after reirradiation; no other grade >3 toxicity was observed.
Reduction in volume and SUV max
Volumes of GTV, CTV, and PTV as well as SUVmax can be found in Table 4 and Supplementary Table 1 . No significant differences in GTV, CTV, or PTV were observed between the three treatment planning phases. However, we observed a trend toward shrinkage of GTV between phase II and phase III (p = 0.05). There was a significant difference in SUVmax between the pretreatment PET and the second pertreatment PET after fraction 18 (p = 0.01).
Discussion
Management of recurrent and second primary HNSCC remains a challenge, with a lower probability of long-term disease control and higher morbidity rates, especially in previously irradiated regions [1, 3] . With this prospective trial we aimed to improve LRC at minimized treatment-induced toxicity with adaptive 18 F-FDG-PET-guided RT, which was based on two concepts:
1. Over the past years, the role of ART in head and neck cancer has been investigated, as correction of per-treatment changes in tumor and OARs could lead to superior dose distributions, particularly important in the previously irradiated territory [14] [15] [16] [17] . Nevertheless, ART is a resource-intensive technique and there is currently no consensus on which patients may benefit most from this treatment strategy [5] . In this respect, Brouwer et al. [18] and Brown et al. [19] recently determined potential selection criteria for ART in head and neck cancer, concluding that this technique might only be beneficial in a minority of patients. 2. The potential of 18 F-FDG-PET-guided dose painting is supported by the hypothesis that FDG uptake is correlated with tumor-cell density, allowing selective doseescalation in more aggressive and/or radioresistant parts of the tumor. A recent review by Min et al. [20] observed a significant association between metabolic parameter(s), for example metabolic tumor volume, of pretreatment 18 F-FDG-PET, and oncologic outcomes in all 52 but 3 studies, supporting the feasibility of 18 F-FDG-PETguided radiation therapy. However, there still is a need for standardized procedures and prospective studies with a reasonably large sample size, homogeneous patient population, and uniform primary treatments.
Since there is a large heterogeneity in patient populations and treatment planning, a lack of prospective trials on highdose RI, and scarceness of data on ART in head and neck cancer, it is difficult to compare our results with other trials. In our trial, 2-year LRC, OS, and DFS were 38, 20, and 20%, respectively. Over the past decade, only four prospective trials on RI have been published. Balermpas et al. [21] reported 1-year local control (LC), OS, and progressionfree survival (PFS) rates of 33, 44, and 33%, respectively, after RI + cetuximab in 18 patients with recurrent or second primary HNSCC. Another trial in 21 patients by Chen et al. [22] observed higher 1-year LRC and OS of 83 and 65%, respectively. Two larger studies by Spencer et al. [23] and Langer et al. [24] demonstrated 1-year OS rates of 41 and 50%, respectively. However, all of these trials had heterogeneous populations, with relatively more recurrent than second primary tumors, used different treatment protocols, and none of them applied adaptive FDG-guided radiation therapy. In several retrospective trials on RI ± systemic therapy, 1-year LRC, OS, and PFS were 64, 44-77, and 36-63%, respectively; at 2-years, LRC, OS, and PFS were 48-59, 32-59, and 23-40%, respectively [2, [25] [26] [27] .
Despite improvements in radiation dose conformity since the implementation of IMRT and ART as well as the introduction of new systemic treatment options, toxicity remains an important problem, especially in previously irradiated patients. Unfortunately, grade 5 toxicity (fatal bleeding) was observed in 2 patients (20%) in our trial, which is higher than in previous RI trials including our own experience with high-dose fractionated RI using non-adaptive IMRT without dose painting by numbers (DPBN), where grade 5 toxicity was observed in 0-9% [2, [21] [22] [23] [24] [25] [26] . Acute toxicity was limited to grade <4 toxicity in all patients, except for one patient with mucosal hemorrhage. Nevertheless, the biggest problem in adaptive 18 F-FDG-PET-guided dose painting and RI seems to be severe late toxicity (from 3 months after treatment onward). Until now, only Madani et al. [28] and Rasmussen et al. [29] have reported on this matter after observing severe late mucosal ulcers at the site of dose-escalation in primary treatment of HNSCC. One of the 2 surviving patients in our trial experienced grade 4 mucosal ulceration at 6 months of follow-up, persistent at last follow-up at 2 years after RI, demonstrating that late toxicity should not be underestimated, even if performing ART and highly conformal techniques such as DPBN.
Although we observed a decrease in the median and mean treatment volumes, we were not able to demonstrate any significant differences in GTV, CTV, and PTV in the different treatment planning phases of the adaptive part of this trial. However, previous planning studies demonstrated potential benefits of ART in the primary treatment of HN-SCC [14] [15] [16] [17] , with more pronounced, significant changes in treatment volume between pretreatment CT and CT on the last day of treatment [30] .
To our knowledge, this study is the first presenting data on changes in SUVmax and tumor volumes in RI of head and neck tumors. When comparing SUVmax between the different PET scans, a significant difference between the pretreatment PET and the second per-treatment PET after fraction 18 was observed. This finding is in contradiction with other studies suggesting an optimal time point of reperforming 18 F-FDG-PET in the first 2 weeks of treatment, as the contrast between tumor and surrounding tissues weakens after 3 weeks of treatment [31] . Bias could be introduced by the fact that SUVmax on 18 F-FDG-PET is influenced by many factors, e. g., patient size, uptake time, plasma glucose, in only 10 patients. The per-treatment changes observed in this study should therefore be interpreted with care [32] .
Another imaging technique that might have potential in ART is hypoxia PET imaging, for example 18 F-fluoromisonidazole ( 18 F-MISO) PET, which can determine hypoxic subvolumes in the tumor. In this respect, it is suggested that dose-escalation to more radioresistant parts of the tumor could be performed in order to diminish the risk of local failure. However, there currently is no consensus that hypoxia PET delivers consistent findings with high reproducibility, since there is a large heterogeneity in short-term changes of tumor hypoxia during radio(chemo)therapy [33, 34] .
A potential source of bias was the decision making on concomitant cetuximab during a multidisciplinary meeting at each participating center. However, we have no indication that this had any influence on the study results.
This trial demonstrated the technical and practical feasibility of adaptive 18 F-FDG-PET-guided RI ± cetuximab. However, due to the slow accrual and the poor survival in our trial, we were not able to demonstrate a benefit of this approach in terms of reduced late toxicity. Since sur-vival is poor in patients with inoperable recurrent head and neck cancer, especially when occurring shortly after the first treatment, the question arises whether these patients could benefit more from stereotactic body radiation therapy (SBRT), known for its hypofractionation and high precision with smaller irradiated volumes, possibly leading to less toxicity and in each case leading to shorter treatment times for patients with dismal prognosis. A prospective phase 2 trial by Vargo et al. [35] on SBRT+ cetuximab in previously irradiated recurrent HNSCC demonstrated a 1-year overall survival of 40% with low acute and chronic grade >3 toxicity rates. These encouraging results are similar to other prospective SBRT reirradiation trials by Ling et al., Comet et al., and Lartigau et al. [36] [37] [38] . Future prospective studies might investigate the potential benefit of 18 F-FDG-PET dose painting combined with hypofractionated SBRT in inoperable recurrent head and neck cancer in an attempt to result in less toxic treatments with at least the same chances for disease control.
Conclusion
Based on our results, we cannot recommend the routine use of adaptive PET-guided reirradiation in a 6-week scheme and it will not be offered in clinical routine in our institute. Larger prospective trials are needed to draw any conclusion, and based on our experience of slow accrual and the existing literature, such trials should be organized by multinational scientific organizations to ensure adequate accrual. Ethical standards All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained, signed, and dated before any protocol procedures were started.
